

Synthesis of Imidazo[1,2-*a*]pyridines from Pyridines and *p*-Bromophenacyl Bromide *O*-Methyloxime

V.A. Artyomov, A.M. Shestopalov, V.P. Litvinov*


N.D. Zelinsky Institute of Organic Chemistry, 117913, Moscow, Russia

Fax +7(095)135 53 28; E-mail LVP\$251@SUEARN2.bitnet

Received 24 November 1995; revised 8 March 1996

p-Bromophenacyl bromide *O*-methyloxime reacts with pyridines in acetone to form the corresponding pyridinium salts which, when heated in methanol in the presence of Et₃N, undergo cyclization followed by elimination of MeOH to give imidazo[1,2-*a*]pyridines.

The imidazo[1,2-*a*]pyridine unit is found in drugs and pesticides and shows a wide spectrum of biological activity.¹ The most common method for the synthesis of imidazo[1,2-*a*]pyridines is the reaction of an α -halocarbonyl compound with an α -aminopyridine (Chichibabin reaction).² These α -aminopyridines are obtained by the amination of pyridines.³ However, the direct amination of pyridines does not always result in the substituted α -aminopyridines, which are not easily accessible. The methods for synthesis of imidazo[1,2-*a*]pyridines based on the cyclization of 2-halo-1-phenacyl pyridinium bromides by treatment with NH₃⁴ or NH₂OH⁵ were also reported. However, the yields of target products are rather low in these cases due to side reactions. Degradation of 2-hydroxyethylcobaloximes⁶ leading to imidazo[1,2-*a*]pyridines proceeds with yields of only about 30%. Elaboration of a synthetic method, which leads to imidazo[1,2-*a*]pyridines without the use of substituted α -aminopyridines with high yields will provide an easy access to this class of compounds. We now report such a new method for the regioselective synthesis of imidazo[1,2-*a*]pyridines using *p*-bromophenacyl bromide *O*-methyloxime (**1**) and pyridines. The oxime ether **1** was prepared from *p*-bromophenacyl bromide and *O*-methylhydroxylamine hydrobromide according to Scheme 1:




Scheme 1

As was shown previously,⁷ the *O*-unsubstituted oxime obtained using these conditions is exclusively the *Z*-isomer. The *Z*-configuration of the oxime ether **1** was confirmed by comparison of its ¹H and ¹³C NMR spectra with the *O*-unsubstituted⁷ compounds.

p-Bromophenacyl bromide *O*-methyloxime (**1**) reacts with pyridines **2a–g** in acetone to form the pyridinium salts **3a–g** (Scheme 2). The *E*-configuration of the oxime group in **3** was established by comparison of their spectra with those of *O*-unsubstituted salts.⁸

We have previously shown⁸ that such *anti*-isomers exist in the fixed configuration, which stipulates the proximity of the nucleophilic *N*-atom of the oxime group to the electron-deficient pyridinium moiety. The *Z* to *E* isome-

rization of the oxime group during quaternization is most likely due to the greater stability of the *anti*-isomer. Such a configuration favors the nucleophilic attack by the *N*-oxime atom on the pyridinium ring. Indeed compounds **3a–g**, when heated in methanol in the presence of Et₃N, undergo cyclization and elimination of MeOH leading to imidazo[1,2-*a*]pyridines **4a–g** (Scheme 2). The cyclization reaction proceeds regioselectively at the most electron-deficient position. In the case of β -picolinium salt **3c**, nucleophilic attack is directed at position 2. This is in agreement with the estimation of the electron density made on the basis of ¹³C NMR spectra of the picolinium salts.⁹ The electron-withdrawing acetyl group directs the reaction towards position 6. This fact is also in agreement with the estimation of electron density.⁹



| 2, 3 | R ¹ | R ² | R ³ |
|------|-------------------------|-------------------------|----------------|
| a | H | H | H |
| b | Me | H | H |
| c | H | Me | H |
| d | H | H | Me |
| e | H | COMe | H |
| f | –(CH=CH) ₂ – | | H |
| g | H | –(CH=CH) ₂ – | |

| 4 | R ¹ | R ² | R ³ | R ⁴ |
|---|-------------------------|----------------|-------------------------|----------------|
| a | H | H | H | H |
| b | Me | H | H | H |
| c | H | H | H | Me |
| d | H | H | Me | H |
| e | H | COMe | H | H |
| f | –(CH=CH) ₂ – | | H | H |
| g | H | H | –(CH=CH) ₂ – | |

Scheme 2

Yields and characterization of compounds **3a–g** and **4a–g** are presented in Tables 1 and 2.

In summary, we have elaborated a novel yet simple method for the regioselective synthesis of imidazo[1,2-*a*]pyridines, which is not based on α -aminopyridines.

IR Spectra were recorded on Specord-M80, ^1H NMR on Bruker WM 250 (250 MHz), ^{13}C NMR on Bruker WM 300 (300 MHz) and mass spectra on Varian Mat CH-6 (70 eV) spectrometers. Elemental analyses were obtained on a Perkin-Elmer C, H, N-analyzer.

p-Bromophenacyl Bromide *O*-Methyloxime (**1**):

To a hot solution of *p*-bromophenacyl bromide (2.00 g, 7.2 mmol) in MeOH (30 mL) was added dropwise water until a slight turbidity was observed. Then *O*-methylhydroxylamine hydrobromide (2.75 g, 21.6 mmol) was added and the resulting mixture was heated to boiling and allowed to stand for 12 h at r. t. The precipitated product was filtered, washed with water (2×20 mL) and dried in the air; yield: 1.80 g (81 %); mp 57–58 °C.

| | | | | |
|--|-------|---------|--------|--------|
| $\text{C}_9\text{H}_9\text{Br}_2\text{NO}$ | calc. | C 35.21 | H 2.96 | N 4.56 |
| (307.2) | found | 35.43 | 2.88 | 4.64 |

Table 1. Pyridinium Salts **3** Prepared

| Prod- uct ^a | Yield (%) | mp (°C) ^b | IR (KBr ₃) ν (cm ⁻¹) | ^1H NMR (DMSO- <i>d</i> ₆ /TMS) δ , <i>J</i> (Hz) |
|---------------------------|--------------|-------------------------|---|---|
| 3a | 64 | 187–188 | 3024, 2920 (CH), 1628 (C=N azine), 1588 (C=N oxime), 1500, 1482, 1450 | 3.98 (s, 3 H, OCH ₃), 6.03 (s, 2 H, CH ₂), 7.63, 7.67 (AA'BB', 4 H, Ar), 8.10 (dd, <i>J</i> = 6, 8, 2 H, 3- and 5-H Py), 8.59 (t, <i>J</i> = 8, 1 H, 4-H-Py), 9.00 (d, <i>J</i> = 6, 2 H, 2- and 6-H Py) |
| 3b | 90 | 232–234 | 3020, 2984, 2936 (CH), 1634 (C=N azine), 1596, 1576 (C=N oxime), 1520 | 2.74 (s, 3 H, 2-CH ₃), 3.96 (s, 3 H, OCH ₃), 5.96 (s, 2 H, CH ₂), 7.54–7.66 (m, 4 H, Ar), 7.90 (dd, <i>J</i> = 6, 8, 1 H, H5), 8.00 (d, 1 H, H3), 8.45 (t, <i>J</i> = 8, 1 H, H4), 8.92 (d, <i>J</i> = 6, 1 H, H6) |
| 3c | 90 | 200–202 | 3028, 2940 (CH), 1632 (C=N azine), 1592 (C=N oxime), 1504, 1474, 1448 | 2.46 (s, 3 H, 3-CH ₃), 3.99 (s, 3 H, OCH ₃), 5.95 (s, 2 H, CH ₂), 7.64, 7.66 (AA'BB', 4 H, Ar), 7.98 (dd, <i>J</i> = 6, 8, 1 H, H-5), 8.42 (d, <i>J</i> = 8, 1 H, H4), 8.77 (d, <i>J</i> = 6, 1 H, H6), 8.87 (s, 1 H, H2) |
| 3d | 75 | 206–207 | 3018, 2935, 2900 (CH), 1637 (C=N azine), 1590 (C=N oxime), 1525, 1473 | 2.56 (s, 3 H, 4-CH ₃), 3.98 (s, 3 H, OCH ₃), 5.90 (s, 2 H, CH ₂), 7.60–7.70 (m, 4 H, Ar), 7.91 (d, <i>J</i> = 6.5, 2 H, H3, H5), 8.77 (d, <i>J</i> = 6.5, 2 H, H2, H6) |
| 3e | 91 | 176–177 | 3060, 3007, 2984 (CH), 1698 (C=O), 1628 (C=N azine), 1592 (C=N oxime) | 2.69 (s, 3 H, COCH ₃), 3.97 (s, 3 H, OCH ₃), 6.07 (s, 2 H, CH ₂), 7.60–7.70 (AA'BB', 4 H, Ar), 8.20 (dd, <i>J</i> = 6, 8, 1 H, H5), 8.99 (d, <i>J</i> = 8, 1 H, H4), 9.03 (d, <i>J</i> = 6, 1 H, H6), 9.50 (s, 1 H, H2) |
| 3f | 83 | 207–208 | 3018, 2997, 2932 (CH), 1624 (C=N azine), 1584 (C=N oxime), 1528, 1480 | 4.05 (s, 3 H, OCH ₃), 6.42 (s, 2 H, CH ₂), 7.39–7.49 (AA'BB', 4 H, Ar), 8.03 (t, <i>J</i> = 7.5, 1 H, H6), 8.13 (dd, <i>J</i> = 6, 8, 1 H, H3), 8.19 (d, <i>J</i> = 7.5, 1 H, H5), 8.29 (t, <i>J</i> = 7.5, 1 H, H7), 8.42 (d, <i>J</i> = 7.5, 1 H, H8), 9.26 (d, <i>J</i> = 8, 1 H, H4), 9.59 (d, <i>J</i> = 6, 1 H, H2) |
| 3g | 80 | 228–229 | 3025, 2997, 2940 (CH), 1640 (C=N azine), 1590 (C=N oxime), 1508, 1490 | 3.99 (s, 3 H, OCH ₃), 6.09 (s, 2 H, CH ₂), 7.63, 7.72 (AA'BB', 4 H, Ar), 8.06 (t, <i>J</i> = 7.5, 1 H, H6), 8.26 (t, <i>J</i> = 7.5, 1 H, H7), 8.32 (d, <i>J</i> = 8, 1 H, H4), 8.48–8.60 (m, 3 H, H3, 5, 8), 10.02 (s, 1 H, H2) |

^a Satisfactory microanalyses obtained: C \pm 0.17, H \pm 0.15, N \pm 0.21.

^b All products were purified by washing with acetone.

Table 2. Imidazo[1,2-*a*]pyridines **4** Prepared

| Prod- uct ^a | Yield (%) | mp (°C) (heptane) | IR (CHCl ₃) ν (cm ⁻¹) | ^1H NMR (CDCl ₃ /TMS) δ , <i>J</i> (Hz) |
|---------------------------|--------------|----------------------|--|--|
| 4a | 96 | 215–216 | 2928, 2856 (CH), 1480, 1470, 1455 | 6.80 (t, <i>J</i> = 6.5, 1 H, H6), 7.20 (dd, <i>J</i> = 6.5, 9, 1 H, H7), 7.57, 7.83 (AA'BB', 4 H, Ar), 7.64 (d, <i>J</i> = 9, 1 H, H8), 7.86 (s, 1 H, H3), 8.12 (d, <i>J</i> = 6.5, 1 H, H5) |
| 4b | 89 | 95–96 | 2932, 2856 (CH), 1588, 1548, 1512, 1476, 1412 | 2.62 (s, 3 H, CH ₃), 6.64 (d, <i>J</i> = 7, 1 H, H6), 7.18 (dd, <i>J</i> = 7, 9, 1 H, H7), 7.50–7.60 (m, 3 H, H8 and Ar), 7.74 (s, 1 H, H3), 7.83–7.90 (m, 2 H, Ar) |
| 4c | 78 | 129–130 | 2988, 2928, 2856 (CH), 1588, 1542, 1476, 1432, 1402 | 2.65 (s, 3 H, CH ₃), 6.67 (t, <i>J</i> = 7, 1 H, H6), 6.95 (d, <i>J</i> = 7, 1 H, H7), 7.53, 7.82 (AA'XX', 4 H, Ar), 7.79 (s, 1 H, H3), 7.95 (d, <i>J</i> = 7, 1 H, H5) |
| 4d | 83 | 204–205 | 2932, 2856 (CH), 1588, 1542, 1476, 1430, 1410 | 2.60 (s, 3 H, CH ₃), 6.61 (d, <i>J</i> = 7, 1 H, H6), 7.55, 7.80 (AA'XX', 4 H, Ar), 7.60 (s, 1 H, H8), 7.82 (s, 1 H, H3), 8.04 (d, <i>J</i> = 7, 1 H, H5) |
| 4e | 83 | 217–218 | 2965, 2845 (CH), 1680 (CO), 1622, 1476, 1430 | 2.64 (s, 3 H, CH ₃), 7.57, 7.82 (AA'XX', 4 H, Ar), 7.64 (d, <i>J</i> = 9.5, 1 H, H8), 7.73 (dd, <i>J</i> = 9.5, 1.5, 1 H, H7), 7.94 (s, 1 H, H3), 8.80 (s, 1 H, H5) |
| 4f | 88 | 174–175 | 2980 (CH), 1602, 1478, 1448, 1416 | 7.50 (t, <i>J</i> = 7.5, 1 H, H7), 7.54–7.65 (m, 4 H, H8, H10 and Ar), 7.68 (t, <i>J</i> = 8, 1 H, H6), 7.84 (d, <i>J</i> = 8, 1 H, H5), 7.88 (m, 2 H, Ar), 7.96 (d, <i>J</i> = 8.5, 1 H, H9), 8.33 (s, 1 H, H3) |
| 4g | 87 | 203–204 | 2930 (CH), 1630, 1478, 1446, 1420 | 7.05 (d, <i>J</i> = 8, 1 H, H6), 7.52–7.73 (m, 5 H, H7, H8, H9 and Ar), 7.81 (s, 1 H, H3), 7.85–7.95 (m, 3 H, H10 and Ar), 8.72 (d, <i>J</i> = 8, 1 H, H5) |

^a Satisfactory microanalyses obtained: C \pm 0.22, H \pm 0.16, N \pm 0.20.

^1H NMR (CDCl_3/TMS): δ = 4.10 (s, 3 H, CH_3), 4.33 (s, 2 H, CH_2), 7.54 and 7.58 (AA'BB', 4 H, Ar).

^{13}C NMR (CDCl_3/TMS): δ = 34.5 (CH_2), 63.6 (CH_3), 123.3 (C4-Ar), 127.6 (C2-Ar), 131.7 (C3-Ar), 134.9 (C1-Ar), 161.2 (C=N).

IR (KBr): ν = 3055 (CH-Ar), 2980 (CH_2), 2898, 2823, 1592 (C=N), 1488, 1463, 1447 cm^{-1} .

MS: m/z = 309, 307, 305 (M^+), 228, 226 ($\text{M}^+ - \text{Br}$).

O-Methyl p-Bromophenacyloximepyridinium Bromides 3a–g;

General Procedure:

To a solution of **1** (3 mmol) in anhyd acetone (15 mL) was added the corresponding pyridine **2** (3 mmol) and the mixture was allowed to stand for 12 h at r. t. Precipitated salt was filtered, washed with acetone, and dried in the air (Table 1).

Imidazo[1,2-a]pyridines 4a–g; Typical Procedure:

To a solution or a suspension of pyridinium salt **3** (2 mmol) in MeOH (20 mL) was added Et_3N (253 mg, 2.5 mmol) and the mixture was refluxed for 4 h. The resulting mixture was poured into water and extracted with CHCl_3 . The CHCl_3 phase was dried (MgSO_4), and passed through a layer of silica gel (5 g) for the removal of gummy products. Removal of solvent afforded practi-

cally pure products. Analytical samples were obtained by recrystallization from heptane (Table 2).

This work was supported by International Science Foundation, Grant No. MEN 300.

- (1) Tominaga, J.; Shiroshita, Y.; Hosomi, A. *Heterocycles* **1988**, 27, 2251.
- (2) Chichibabin, A. E. *Ber. Dtsch. Chem. Ges.* **1925**, 58, 1706.
- (3) McGill, C. K.; Rappa, A. *Adv. Heterocycl. Chem.* **1988**, 44, 1.
- (4) Kröhnke, F.; Kickhöfen, B.; Thoma, C. *Chem. Ber.* **1955**, 88, 1117.
- (5) Hand, E. S.; Paudler, W. W. *J. Org. Chem.* **1978**, 43, 658.
- (6) Alcock, N. W.; Golding, B. T.; Hall, D. R.; Horn, U.; Watson, W. P. *J. Chem. Soc. Perkin Trans. 1* **1975**, 386.
- (7) Smith, J. H.; Heidema, J. H.; Kaiser, E. T.; Wetherington, J. B.; Moncrief, J. W. *J. Am. Chem. Soc.* **1972**, 94, 9274.
- (8) Artyomov, V. A.; Shestopalov, A. M.; Litvinov, V. P. *Zh. Org. Khim.* **1995**, 31, 595.
- (9) Boulton, A. J.; McKillop, A. In *Comprehensive Heterocyclic Chemistry*; Katritzky, A. R.; Rees, C. W., Eds.; Pergamon: 1984, Vol. 2, p 12.